# ğŸ“… Daily Report - 2025-11-04

> ä»Šæ—¥ç­›é€‰å‡º **17** æ¡å†…å®¹ï¼Œæ¥è‡ª **3** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ“° å…¬ä¼—å·

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
åŸºäºå•ç»†èƒæµ‹åºæ„å»ºç»†èƒè¡°è€ç»†èƒç±»å‹ç‰¹å¼‚æ€§å›¾è°±ï¼Œå¹¶è‡ªå®šä¹‰ç®—æ³•é‰´å®šå‡ºæ–°çš„è¡°è€åŸºå› é›†ï¼Œæ˜¯æœ¬æ¬¡ä¿¡æ¯æ›´æ–°ä¸­çš„ä¸€å¤§çªç ´ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   **ç»†èƒè¡°è€ç ”ç©¶**ï¼šèšç„¦éè‚¿ç˜¤å’Œè‚¿ç˜¤ç–¾ç—…ä¸­ç»†èƒè¡°è€çš„ç‰¹å¾ã€è¡¨å‹åŠåœ¨ç–¾ç—…ä¸­çš„ä½œç”¨ï¼ŒåŒ…æ‹¬è¡°è€åœ¨å…ç–«è€åŒ–ä¸­çš„åº”ç”¨ã€‚
*   **ç–¾ç—…åˆ†å‹ä¸æ¨¡å‹æ„å»º**ï¼šåˆ©ç”¨ç»†èƒæ­»äº¡å’Œè¡°è€ç›¸å…³æ•°æ®ï¼Œè¿›è¡Œè‚¿ç˜¤åˆ†å‹åŠæ¨¡å‹æ„å»ºã€‚
*   **CAFï¼ˆè‚¿ç˜¤ç›¸å…³æˆçº¤ç»´ç»†èƒï¼‰ç ”ç©¶**ï¼šæ·±å…¥æ¢è®¨CAFçš„è¡°è€è¡¨å‹ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   **æœºå™¨å­¦ä¹ ä¸å•ç»†èƒåˆ†æ**ï¼šå¹¿æ³›åº”ç”¨äºç»†èƒè¡°è€ç‰¹å¾æŒ–æ˜ã€PANoptosisçƒ­ç‚¹ç ”ç©¶ã€CAFè¡°è€è¡¨å‹åˆ†æç­‰ã€‚
*   **å¤šç»„å­¦æ•´åˆä¸å·¥å…·å¼€å‘**ï¼šåŒ…æ‹¬ç©ºé—´å¤šç»„å­¦æ™ºèƒ½æ•´åˆã€å•ç»†èƒæ‰¹æ¬¡æ•´åˆã€å¯å˜å‰ªåˆ‡åˆ†æåŠå‘è‚²æ½œèƒ½é¢„æµ‹ç­‰æ–°å·¥å…·çš„å‡ºç°ã€‚

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
é¦–æ¬¡æ­ç¤ºäº†**å…ˆé©±è½¬å½•å› å­**å¦‚ä½•é€šè¿‡è°ƒæ§**æ ¸å°ä½“åŠ¨åŠ›å­¦**å’Œ**è¡¨è§‚é—ä¼ ç›¸äº’ä½œç”¨**æ¥é©±åŠ¨ç»†èƒåˆ†åŒ–ï¼ˆGSE268719ï¼‰ï¼›åŸºäº**é…ä½“åŠŸèƒ½åŒ–çš„CRISPR-Cas9**ï¼Œå®ç°äº†**G-å››é“¾ä½“**çš„é¶å‘è°ƒæ§ï¼Œå¹¶å‘ç°äº†å…¶**è½¬å½•ä¾èµ–æ€§çš„åŠŸèƒ½å“åº”**ï¼ˆGSE279769ï¼‰ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- æ¢ç´¢å…ˆé©±è½¬å½•å› å­åœ¨æ ¸å°ä½“åŠ¨æ€é‡å¡‘ä¸ç»†èƒåˆ†åŒ–ä¸­çš„åˆ†å­æœºåˆ¶ã€‚
- åˆ©ç”¨CRISPR-Cas9æŠ€æœ¯å®ç°G-å››é“¾ä½“çš„ç²¾å‡†é¶å‘ä¸åŠŸèƒ½è§£æã€‚
- é€šè¿‡è½¬å½•ç»„å­¦ç ”ç©¶ï¼Œæ˜ç¡®Hedgehogä¿¡å·é€šè·¯åœ¨MÃ©nÃ©trierç—…å‘ç—…æœºåˆ¶åŠä½œä¸ºç”Ÿç‰©æ ‡å¿—ç‰©ä¸­çš„ä½œç”¨ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- **é…ä½“åŠŸèƒ½åŒ–CRISPR-Cas9**ï¼šå®ç°å¯¹ç‰¹å®šDNAç»“æ„ï¼ˆG-å››é“¾ä½“ï¼‰çš„ç²¾ç¡®ç¼–è¾‘ä¸è°ƒæ§ã€‚
- **é«˜é€šé‡æµ‹åº**ï¼ˆExpression profiling, Genome binding/occupancy profilingï¼‰ï¼šç”¨äºè§£æåŸºå› è¡¨è¾¾å’ŒæŸ“è‰²è´¨ç»“åˆçš„åŠ¨æ€å˜åŒ–ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
å•ç»†èƒRNAæµ‹åºé¦–æ¬¡æ­ç¤ºäº†å·¨å™¬ç»†èƒä¸­çš„å¹²æ‰°ç´ ä¿¡å·é€šè·¯å¦‚ä½•é©±åŠ¨è‚¾ç™Œå…ç–«æ²»ç–—è€è¯æ€§ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- è‚¾ç»†èƒç™Œå…ç–«æ²»ç–—è€è¯æœºåˆ¶ç ”ç©¶
- ç–¾ç—…ç›¸å…³åŸºå› ï¼ˆå¦‚MAPT, BIN1ï¼‰çš„å‰ªæ¥è°ƒæ§æœºåˆ¶è§£æ
- å…½åŒ»è¯Šæ–­ä¸åŠ¨ç‰©å¥åº·ç›‘æµ‹ä¸­çš„ç—…åŸä½“å¿«é€Ÿæ£€æµ‹

**æŠ€æœ¯äº®ç‚¹**ï¼š
- åˆ©ç”¨é•¿è¯»é•¿RNAæµ‹åºæŠ€æœ¯ï¼ˆisoLASERï¼‰åŒºåˆ†é¡ºå¼å’Œåå¼å‰ªæ¥è°ƒæ§ã€‚
- å•ç»†èƒRNAæµ‹åºåœ¨è‚¿ç˜¤å…ç–«ç ”ç©¶ä¸­çš„åº”ç”¨ã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (11æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **éè‚¿ç˜¤çº¯ç”Ÿä¿¡ï¼ŒåŸºäºæœºå™¨å­¦ä¹ ï¼Œæ— ç›‘ç£èšç±»ç­‰ç ”ç©¶ç»†èƒè¡°è€åœ¨ç–¾ç—…ä¸­çš„ç‰¹å¾ã€‚è¡°è€çƒ­ç‚¹ç»ä¹…ä¸è¡°ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡ã€èšç±»
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=2&sn=c47f1a491567d4f934a11206dce7e27a)

**2.** â­ **æœ€æ–°8.1åˆ†éè‚¿ç˜¤ç”Ÿä¿¡ï¼Œé’ˆå¯¹PANoptosisçƒ­ç‚¹è¿›è¡Œæœºå™¨å­¦ä¹ +å•ç»†èƒç­›é€‰+ç®€å•éªŒè¯ï¼Œå…¨æ–‡åªæœ‰4ä¸ªFigureï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€å•ç»†èƒã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=1&sn=57ca959a005a04d9cd4410f16d895348)

**3.** â­ **å¤æ—¦å¤§å­¦å‘ Nat Cancer |ä¸´åºŠè¯•éªŒ+å•ç»†èƒæµ‹åºï¼Œçœ‹çœ‹ä»–ä»¬æ˜¯æ€ä¹ˆåšçš„**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡é’±åŒå­¦
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€æµ‹åºã€å•ç»†èƒ
- ğŸ“ **æè¿°**ï¼šä¸´åºŠå®éªŒé…åˆå•ç»†èƒæµ‹åº
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&mid=2247495403&idx=1&sn=464b38cbd7349648d4d8113aec4d6f0c)

**4.** **å¥åº·æˆå¹´äººå…ç–«è€åŒ–å…¨æ™¯å›¾ï¼›ç©ºé—´å¤šç»„å­¦æ™ºèƒ½æ•´åˆä¸è°ƒæ§ç½‘ç»œæ¨æ–­ã€å•ç»†èƒæ‰¹æ¬¡æ•´åˆã€å•ç»†èƒå¯å˜å‰ªåˆ‡ã€å‘è‚²æ½œèƒ½é¢„æµ‹ç­‰å·¥å…·ä¸Šæ–° |å•ç»†èƒè§†è§’**
- âœï¸ **ä½œè€…**ï¼šå•ç»†èƒå¤©åœ°
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå•ç»†èƒã€ç©ºé—´ç»„å­¦
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&mid=2247533477&idx=1&sn=daf8c8ee0fd42dcd889437aac72a9a76)

**5.** **æœ€æ–°5.7åˆ†ç”Ÿä¿¡ï¼Œå•ç»†èƒæ³›ç™Œ+ç©ºè½¬æ³›ç™Œ+ç™¾ç§æœºå™¨å­¦ä¹ ç ”ç©¶CAFçš„è¡°è€è¡¨å‹ï¼ŒæŠ•ç¨¿åˆ°æ¥æ”¶ä»…48å¤©ï¼Œå¯è°“æ˜¯æ°´åˆŠä¸­çš„å¤©èŠ±æ¿ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå•ç»†èƒã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=7&sn=a41c1eee969ebc64c35bd1079c262907)

**6.** **5æœˆæœ€æ–°10+ç”Ÿä¿¡ï¼ŒåŸºäºç»†èƒæ­»äº¡å’Œè¡°è€çš„è‚¿ç˜¤åˆ†å‹åŠæ¨¡å‹æ„å»ºï¼Œåˆ†æä¸éš¾ï¼Œå®éªŒåªæœ‰åŠä¸ªfigureï¼Œå€¼å¾—å­¦ä¹ ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=6&sn=34a846bbfdc98165c172a8b3b8d8f4ef)

**7.** **9.4åˆ†éè‚¿ç˜¤ç”Ÿä¿¡ï¼Œè¡°è€+æœºå™¨å­¦ä¹ +åˆ†å‹+å…ç–«æµ¸æ¶¦+è¡¨è¾¾éªŒè¯ã€‚è¿™æˆ‘ä¹Ÿèƒ½åšå‘€ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=4&sn=8f76b0533d1a608e8bb2ea6c4d894ade)

**8.** **15.7åˆ†çº¯ç”Ÿä¿¡ï¼ŒåŸºäºå•ç»†èƒæ„å»ºç»†èƒè¡°è€çš„ç»†èƒç±»å‹ç‰¹å¼‚æ€§å›¾è°±ã€‚è‡ªå®šä¹‰ç®—æ³•é‰´å®šå‡ºæ–°çš„è¡°è€åŸºå› é›†ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå•ç»†èƒã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503824&idx=3&sn=1eacdde390df0a070b63975b9c529cbe)

**9.** **è›‹ç™½è´¨ç»„è½¬å½•ç»„åˆ†æä¸¤ä¸‰äº‹ï¼šKEGGå·²ç»ä¸æ˜¯ä»¥å‰çš„KEGGäº†**
- âœï¸ **ä½œè€…**ï¼šDr.Xçš„åŸºå› ç©ºé—´
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè½¬å½•ç»„ã€è›‹ç™½è´¨ç»„
- ğŸ“ **æè¿°**ï¼šæ—§ä»£ç éœ€è¦å®šæœŸæ£€æŸ¥è¿è¡Œç¨³å®šæ€§ï¼Œç‰¹åˆ«æ˜¯ä»£ç ä¸­ä¾èµ–åˆ°ç¬¬ä¸‰æ–¹æ•°æ®åº“å’Œç½‘ç«™æ—¶ï¼Œéœ€è¦è­¦æƒ•å¤–éƒ¨å˜åŒ–ä¸ºå†…éƒ¨åˆ†æå¸¦æ¥ä¸å¯å¿½è§†çš„å½±å“
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzU3MTc2NDI4Mw==&mid=2247486659&idx=1&sn=b3d0fd6f227a91f5306e359763dbb5ed)

**10.** **åˆ°ç°åœ¨è¿˜ä¸ä¼šç”¨ggforceåŒ…ï¼Ÿä¸‰åˆ†é’Ÿå¸¦ä½ ç©è½¬é«˜çº§æ•°æ®å¯è§†åŒ–ï¼Œè®©ä½ çš„å›¾è¡¨ç¬é—´é«˜å¤§ä¸Šï¼**
- âœï¸ **ä½œè€…**ï¼šäº‘ç”Ÿä¿¡
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRåŒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&mid=2247498404&idx=1&sn=d6615b113ae6d19bc0137f3cbfe0ed10)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 1 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-å…¬ä¼—å·)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (3æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰

**1.** â­ **GSE268719 å…ˆé”‹è½¬å½•å› å­ä¹‹é—´çš„åˆ†å­å’Œä¸Šä½æ€§ç›¸äº’ä½œç”¨å¡‘é€ æ ¸å°ä½“åŠ¨åŠ›å­¦å’Œç»†èƒåˆ†åŒ–**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€carcinomaã€scRNAã€scDNAã€scATACã€spatialã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€proteomeã€proteomicsã€metabolomeã€metabolomicsã€Seuratã€Scanpyã€methylationã€enrichmentã€resistance
- ğŸ“ **æè¿°**ï¼šContributors : RÃ©mi-Xavier Coux ; Pablo NavarroSeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268719)

**2.** â­ **GSE279769 åˆ©ç”¨é…ä½“åŠŸèƒ½åŒ–çš„ CRISPR-Cas9 å¯¹å•ä¸ª G-å››é“¾ä½“è¿›è¡Œé¶å‘ï¼Œæ­ç¤ºäº†è½¬å½•ä¾èµ–æ€§åŠŸèƒ½ååº”ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€Hi-Cã€single.cellã€single-cellã€scRNAã€scDNAã€scATACã€spatialã€Seuratã€epigeneticã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Sabrina Pia Nuccio ; Enrico Cadoni ; Roxani Nikoloudaki ; Silvia Galli ; An-Jie Ler ; Thomas E Maher ; Ella Fan ; Ling Sum Liu ; Christopher R Fullenkamp ; John S Schneekloth Jr ; Marco Di AntonioSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe development of selective ligands to target DNA G-quadruplexes (G4s) has been pivotal in revealing their role in transcriptional regulation. However, most of the ligands described to date lack intra-G4 selectivity, severely limiting their potential for uncovering the biological function of individual G4s across the genome. To overcome these limitations, we developed ATENA (Approach to Target Exact Nucleic Acid alternative structures). ATENA relies on the chemical modification of established G4-ligands to enable their conjugation onto a catalytically inactive Cas9 protein (dCas9) using HaloTag, allowing for the targeting of individual G4s in living cells. We have systematically screened the length of the PEG-linkers connecting the G4-ligands to the HaloTag and sgRNA sequences to attain optimal G4 engagement both in vitro and in cells. Using optimized conditions, we leveraged ATENA to demonstrate how the selective targeting of the well-studied G4 in the promoter of the oncogene c-MYC suppresses its transcription exclusively from the P1 promoter. We also show that positioning ligands in the proximity of regulatory elements suppresses c-MYC transcription in a G4-independent manner, highlighting the importance of appropriate design to measure genuine G4-mediated transcriptional changes. We also demonstrate that selective targeting of a G4 in the PVT1 promoter can either stimulate or repress its transcription depending on the type of G4-ligand used, indicating that functional responses associated with G4-stabilization can highly depend on the type of ligand used. We further harnessed ATENA to study transcriptional perturbation associated with cell-specific G4s, revealing that the functional responses associated with these structures are tightly linked with the expression levels of the targeted gene. Our study provides critical insights into G4-based therapeutic design, offering an innovative platform to investigate G4 biology with high precision.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279769)

**3.** â­ **GSE277340è½¬å½•ç»„åˆ†ææ­ç¤ºäº†Hedgehogä¿¡å·é€šè·¯ä½œä¸ºç”Ÿç‰©æ ‡å¿—ç‰©åœ¨æ¢…å†…ç‰¹é‡Œå°”ç—…å‘ç—…æœºåˆ¶ä¸­çš„ä½œç”¨**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šscRNAã€scDNAã€spatialã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€proteomeã€epigenomeã€histoneã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : Miyoung Shin ; Tryston T Gabriel ; Fred Kwame Ofosu ; Jiali Zhang ; Tricia T Wang ; Matthew E Bechard ; Robert J Coffey ; Won Jae HuhSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBoth MÃ©nÃ©trierâ€™s disease (MD) and juvenile polyposis syndrome (JPS) are rare premalignant conditions that can lead to gastric cancer. MD is an acquired disease without known causative mutations that is characterized by increased expression of an EGF receptor (EGFR) ligand, transforming growth factor-alpha (TGFÎ±), in the stomach. JPS is inherited in an autosomal dominant pattern and is caused by BMPR1A or SMAD4 mutations. Although there are distinct clinico-pathological features that differ between the two diseases, they also share similar features that often lead to misdiagnosis. To identify diagnostic markers for MD and to better understand the pathogenesis of the disease, we performed transcriptomic profiling of stomach tissues from normal (NL), MD, and JPS patients. Comparative analysis between MD and JPS revealed both common and differential gene signatures. Common gene signatures included estrogen receptor signaling, integrin signaling, mTOR signaling, and others, which may be responsible for histopathological similarities. Among differential gene signatures, we found that Hedgehog (Hh) signaling is upregulated in MD and confirmed that protein expression of Hh signaling downstream targets, GLI1 (glioma-associated oncogene homolog 1) and HHIP (Hedgehog-interacting protein), is higher in MD than in JPS, particularly in foveolar cells by immunohistochemistry. We also showed that treatment with an Hh pathway inhibitor partially rescued the histopathological phenotypes in an MD mouse model. This study provides valuable insights into the potential mechanisms underlying the similar clinico-pathological features observed in MD and JPS. We also identified GLI1 and HHIP as diagnostic markers that can help to distinguish MD from JPS. Furthermore, Hh signaling was shown to play an important role in the pathogenesis of MD and can function as a potential therapeutic target.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277340)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰

**1.** â­ **åˆ©ç”¨å•ç»†èƒRNAæµ‹åºè§£ç è‚¾ç™Œä¸­çš„å¹²æ‰°ç´ ä¿¡å·é€šè·¯**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€sequencingã€RNA-seqã€RNAseqã€DNA-seqã€Hi-Cã€single.cellã€single-cellã€scRNAã€scATAC
- ğŸ“ **æè¿°**ï¼šSingle-cell RNA sequencing reveals how interferon signaling in macrophages drives resistance to immunotherapy in renal cell carcinoma, offering new insights for biomarker discovery and treatment strategies...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/decoding-interferon-signaling-in-kidney-cancer-with-single-cell-rna-sequencing/)

**2.** â­ **isoLASERé•¿è¯»é•¿RNAæµ‹åºå¯åŒºåˆ†é¡ºå¼å’Œåå¼å®šå‘çš„RNAé€‰æ‹©æ€§å‰ªæ¥**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€RNA-seqã€RNAseqã€DNA-seqã€scRNAã€scDNAã€scATACã€resistance
- ğŸ“ **æè¿°**ï¼šRNA sequencing using long-read technology reveals how cis- and trans-acting elements control splicing in disease-related genes including MAPT and BIN1...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/isolaser-long-read-rna-seq-demarcates-cis-and-trans-directed-alternative-rna-splicing/)

**3.** â­ **ä»å®éªŒå®¤åˆ°ç”Ÿç‰©ä¿¡æ¯å­¦ï¼šæ„å»ºä¸‹ä¸€ä»£åŸºå› æµ‹åºç½‘ç»œ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsequencingã€RNAseqã€bioinformaticsã€histone
- ğŸ“ **æè¿°**ï¼šRNA sequencing advances are empowering veterinary diagnosticians to detect emerging pathogens faster and improve animal health surveillance through hands-on training in next-generation sequencing and bioinformatics...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/from-bench-to-bioinformatics-networking-the-next-generation-in-genetic-sequencing/)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| ç”Ÿä¿¡ | 7 |
| å•ç»†èƒ | 5 |
| cancer | 5 |
| scRNA | 5 |
| è‚¿ç˜¤ | 4 |
| scATAC | 4 |
| scDNA | 4 |
| RNAseq | 3 |
| histone | 3 |
| spatial | 3 |
| sequencing | 2 |
| RNA-seq | 2 |
| DNA-seq | 2 |
| Hi-C | 2 |
| single.cell | 2 |
| single-cell | 2 |
| resistance | 2 |
| Seurat | 2 |
| genome | 2 |
| genomics | 2 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (1æ¡)</summary>

<div class="details-content" markdown="1">

- [å†¬å¤©åˆ°äº†ï¼Œç©ºè°ƒç”µè´¹çœäº†ï¼Œç»™å¤§å®¶åšç‚¹æœåŠ¡å™¨åŒ 11 æ´»åŠ¨ï¼Œä¾¿æ·å¼ç”Ÿä¿¡äº‘æœåŠ¡å™¨](https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&mid=2247495414&idx=1&sn=80a30c4ee87a6a6bb2bf379eafbb6847)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-03 21:41*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*